Home News BlockChain news Tightened EU Regulations Enabling Blockchain Technology in Pharmaceutical Supply Chain

Tightened EU Regulations Enabling Blockchain Technology in Pharmaceutical Supply Chain

51 min read
0
167
Tightened EU Regulations Enabling Blockchain Technology in Pharmaceutical Supply Chain  Tightened EU Regulations Enabling Blockchain Technology in Pharmaceutical Supply Chain 11

Blockchain technology has the potential to create new foundations for global businesses. Its provision of an immutable, global, online ledger for transactions that includes a verification mechanism will undoubtedly lead to disruptive innovations across all sectors. While most Blockchain investors have seen interesting applications in fintech, the Switzerland based modum.io is one of the few start-ups focused on the 8.1 trillion USD global logistics market.

In particular, modum.io is focusing on the highly regulated pharmaceutical logistics market, which currently relies on old and expensive methods in order to meet new regulations. modum.io tackles the market need for new, cost effective alternatives for compliance with sensor devices and a Blockchain back-end.

Oversubscribed Pre-Token Sale – Public Token Sale starts September 1st

To finance the market entry of their Blockchain based temperature monitoring system, modum.io announced on August 14th that it would hold a public token sale beginning September 1st. Its invite only pre-sale was oversubscribed within one day, selling 2.1 million tokens. modum.io is one of the few companies offering profit participation and voting rights with their token.

These benefits to investors and the maturity of the start-up (it has a working product, commercial traction, major partnerships, and hardware ready for mass production) makes this public token sale a highly anticipated opportunity for investors in the Blockchain space. The funds raised will be used to bring the first product to market and to further develop the modum system.

Regulatory driven first application

The new EU GDP regulation (GDP 2013/C 343/01) requires proof that shipped medicines have not been exposed to conditions, particularly temperatures, which may compromise their quality. These regulations are now enforced across Europe. It is likely that regulations in the United States (draft chapter 1083: “Good Distribution Practice”) will follow suit, in a similar direction.

To date, pharmaceutical companies meet requirements via expensive, temperature-stabilized trucks and containers from third-party logistics providers. For the majority of medicines, which are not temperature sensitive, this is excessive from a cost and regulatory perspective.

“Our system reduces the need for costly and inefficient actively-cooled transport solutions. Logistics services could save up to 3 billion EUR annually with our passive monitoring strategy,” explains CEO Malik El Bay.

The modum system offers an alternative supply-chain solution, ensuring GDP compliance and auditability. The sensor devices record the environmental conditions (temperature, humidity, movement, etc.) that a shipment has been exposed to while in transit; senders can pre-program these alarm criteria into the Blockchain. The sender and the receiver will then be notified if a deviation in conditions, that may affect the quality of the product, has occurred. The records are immutable and auditable.

According to El Bay:
“After testing our system with several leading pharma distribution companies and implementing their feedback, we have begun preparation for the mass production of the first batch of sensor devices.”

The commercial launch of the modum system is planned for Q1 2018. Until then the start-up is focused on its token sale, which starts September 1st, and the ongoing integration of the system with select logistic service provider market leaders.

Source: goo.gl/reMM5q

Check Also

Australia and UK “Concluding Negotiations” for New FinTech Deal

The Australian High Commissioner to the UK has revealed that the two countries are on the …